Loading viewer...
investor_presentation
Format: PDF investor_presentation
H1 2024 Results Presentation 22 August 2024 ASX: TLX Illustration showing TLX250 binding to carbonic anhydrase IX and internalisation Zircaix® -PET avid PSMA -PET negative Credit: UCLA expanded access program
Illustration showing TLX250 binding to
carbonic anhydrase IX and internalisation
Credit: UCLA expanded access programDisclaimer
2This presentation should be read in conjunction with our most recent reports and announcements, including our risk factors, lodged with the Australian Securities Exchange (ASX) or on our website .
The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction,
including the United States . The information and opinions contained in this presentation aresubject to change without notification .To the maximum extent permitted by law, Telix disclaims any obligation or
undertaking to update or revise any information or opinions contained in this presentation, including any forward -looking statements (as referred to below) contained in this presentation, whether as a result of
new information, future developments, a change in expectations or assumptions, or otherwise . No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the
information contained or opinions expressed in this presentation .
This presentation may contain forward -looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments . Forward - looking statements can
generally be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
or “would,” or the negative of these words or other similar terms or expressions . Forward -looking statements involve known and unknown risks, uncertainties and other factors that may cause Telix’s actual
results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward -looking statements .
Forward -looking statements are based on Telix’s good -faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the
future . In the context of Telix’s business, forward -looking statements may include, but are not limited to, statements about : the initiation, timing, progress and results of Telix’s preclinical and clinical trials,
Telix’s research and development programs ; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi -national clinical trials ; the timing or likelihood of
Preview truncated — download the full document for the complete content.
annual_report
14 Pages
investor_presentation
19 Pages
WSP Global